Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 556 of 1,261

  1. US 10016491

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    HALOZYME, INC. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  2. US 10016498

    D-amino acid derivative-modified peptidoglycan and methods of use thereof

    The Regents of the University of California · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  3. US 10016499

    Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same

    Northwestern University · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  4. US 10016490

    Multiple-enzyme nanocomplexes

    The Regents of the University of California · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  5. US 10016486

    Methods and compositions using AMPK activators for pharmacological prevention of chronic pain

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  6. US 10016480

    Peptide-based methods for treating pancreatic cancer

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  7. US 10016465

    Cured gel and method of making

    ATRIUM MEDICAL CORPORATION · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  8. US 10016484

    Methods of treating lung cancer

    Five Prime Therapeutics, Inc. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  9. US 10016452

    Fibromodulin formulation for reducing corneal scarring

    The Regents of the University of California · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  10. US 10016437

    Drug combinations and uses in treating a coughing condition

    Infirst Healthcare Limited · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  11. US 10016463

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  12. US 10016461

    Apparatus and process for growing a heart valve in three-dimensions

    The Regents of the University of California · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  13. US 10016432

    Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  14. US 10016399

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  15. US 10010587

    IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

    Nektar Therapeutics · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  16. US 10011649

    High affinity synbodies for influenza

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  17. US 10011647

    IL-33 antagonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  18. US 10011589

    Treatments for gastrointestinal conditions

    The Board of Regents of the University of Texas System · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  19. US 10012653

    Nanoparticles for targeting acid tumor microenvironments

    The Board of Regents of the University of Texas System · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  20. US 10011833

    Bridged bicyclic nucleosides

    MIRAGEN THERAPEUTICS, INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  21. US 10011682

    Method of preparing carboxylic acid functionalized polymers

    Nektar Therapeutics · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  22. US 10011562

    Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  23. US 10010622

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

  24. US 10010600

    Compositions and methods for administration of vaccines against dengue virus

    Takeda Vaccines, Inc. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.